New Cancer Vaccine, mRNA, to Trigger Anti-Cancer Response in Immune Systems

Scientists at the University of Florida have recently developed an experimental mRNA (messenger RNA) vaccine to induce the production of proteins within the cells. These proteins, in turn, regulate the body's immune response. Hence, the body can react well to cancer treatments.

Scientists have been working on this vaccine for over eight years. According to experts, this vaccine increased the PD-L1 protein within the cancerous tumours. Hence, the cells became more reactive than in the previous cases.

Dr. Elias Sayour is a paediatric oncologist and chief investigator at the RNA Engineering Laboratory at the University of Florida’s Preston A Wells Jr. Centre for Brain Tumour Therapy. According to him, this vaccine doesn’t target a specific virus or protein. Hence, it could be used to sensitise a cancer patient’s immune system against their own tumours.

By not targeting cancer proteins and focusing on stimulating the immune system’s reactions, this vaccine can result in patients exhibiting anti-cancer reactions. Therefore, it has the potential to become a fast-selling cancer vaccine in the near future, if its applications are studied in detail, according to cancer specialists.

Source: The Economic Times